Key Metrics
2.9
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
Q4
Toxicology
SJR
- Q4 Toxicology
- Q3 Pharmacology
- Q3 Pharmacology (medical)
SJR
SJR
SCImago Journal Rank measures weighted citations received by the serial. Citation weighting depends on subject field and prestige (SJR) of the citing serial.
0.68
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Indexed in the following public directories
-
Web of Science -
Scopus -
SJR
Topics Covered
- Psoriasis
- Antimicrobial
- Rash
- Xylometazoline
- Minocycline
- Ethambutol
- Cardiovascular safety
- Antidiabetic agents
- Bisoprolol
- Delirium
- Metformin
- Type 2 Diabetes Mellitus
- Sulfonylurea
- Alpha-glucosidase inhibitor
- Lichenoid drug eruption
- Heart failure
- Levofloxacin
- Semaglutide
- Potentially Inappropriate Medications
- Safety profile
Journal Specifications
| Overview | |
| Publisher | BENTHAM SCIENCE PUBL |
| Language | English |
| Frequency | Tri-annual |
| General Details | |
| Language | English |
| Frequency | Tri-annual |
| Publication Start Year | 2006 |
| Publisher URL | Visit website |
| Website URL | Visit website |
Planning to publish in Current Drug Safety ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
SGLT-2 Inhibitors as an Effective Treatment for Type 2 Diabetes Mellitus, Hypertension, and Hyperuricemia - A Mechanistic Perspective.
- 22 Nov 24
- Current drug safety
-
Full paper
Carbamazepine-induced Stevens-Johnson Syndrome: A Case Report with Review of the Literature.
- 5 Nov 24
- Current drug safety
-
Full paper
Cyclophosphamide Toxicity in Pediatric Nephrotic Syndrome Patient: A Case Report and Literature Review.
- 1 Nov 24
- Current drug safety
-
Full paper
Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures.
- 1 Nov 24
- Current drug safety
-
Full paper
A Review of Drug Abuse, Misuse, and Related Laboratory Challenges.
- 1 Nov 24
- Current drug safety
-
Full paper
Erythema Multiforme Reactions Following Pfizer/BioNTech (Tozinameran) Vaccination: Two Case-Reports with Positive Rechallenge and Review of the Literature.
- 1 Nov 24
- Current drug safety
Scite analysis
Powered by scite_
1k articles received 8k citations see all
- 256 Supporting
- 7,391 Mentioning
- 57 Contrasting
Editorial notices
- 2 Retractions
- 1 Withdrawals
- 0 Corrections
- 1 Errata
- 0 Expression of Concern
FAQs
How long has Current Drug Safety been actively publishing?
Current Drug Safety has been in operation since 2006 till date.
What is the publishing frequency of Current Drug Safety ?
Current Drug Safety published with a Tri-annual frequency.
How many articles did Current Drug Safety publish last years ?
In 2023, Current Drug Safety published 85 articles.
What is the eISSN & pISSN for Current Drug Safety ?
For Current Drug Safety,eISSN is 2212-3911 and pISSN is1574-8863.
What is Citescore for Current Drug Safety ?
Citescore for Current Drug Safety is 2.9.
What is SNIP score for Current Drug Safety ?
SNIP score for Current Drug Safety is 0.68.
What is the SJR for Current Drug Safety ?
SJR for Current Drug Safety is Q4.
Who is the publisher of Current Drug Safety ?
BENTHAM SCIENCE PUBL is the publisher of Current Drug Safety.